Rxsight Inc Net Assets
Rxsight Inc net assets. Based on the latest financial reports, Rxsight Inc (RXST) has net assets worth $263.34 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($352.70 Million) and total liabilities ($89.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Rxsight Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $263.34 Million |
| % of Total Assets | 74.66% |
| Annual Growth Rate | N/A |
| 5-Year Change | 99.42% |
| 10-Year Change | N/A |
| Growth Volatility | 49.09 |
Net Assets of Rxsight Inc (2019–2025)
Net assets of Rxsight Inc from 2019 to 2025. This chart illustrates how Rxsight Inc's net assets have evolved over time, based on quarterly financial data. See RXST equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Rxsight Inc (2019–2025)
The table below shows the annual net assets of Rxsight Inc from 2019 to 2025. For live market cap and overall valuation, see market cap of Rxsight Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $275.68 Million | -1.98% |
| 2024-12-31 | $281.24 Million | +75.38% |
| 2023-12-31 | $160.36 Million | +78.37% |
| 2022-12-31 | $89.90 Million | -34.97% |
| 2021-12-31 | $138.24 Million | +146.46% |
| 2020-12-31 | $-297.53 Million | +2.32% |
| 2019-12-31 | $-304.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rxsight Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24118400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Rxsight Inc Net Assets Breakdown (December 2025)
Rxsight Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $41.00K | 0.01% |
| Other Comprehensive Income | $53.00K | 0.02% |
| Other Components | $936.63 Million | 339.75% |
| Total Equity | $275.68 Million | 100.00% |
Rxsight Inc Competitors by Market Cap
The table below lists competitors of Rxsight Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medical Facilities Corporation
TO:DR
|
$190.94 Million |
|
Ndr Auto Components Limited
NSE:NDRAUTO
|
$191.02 Million |
|
Jiangsu Zhongshe Group Co Ltd
SHE:002883
|
$191.03 Million |
|
HARIM Co. Ltd
KQ:136480
|
$191.06 Million |
|
Josef Manner & Comp. AG
VI:MAN
|
$190.89 Million |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
$190.81 Million |
|
Optimum Communications, Inc.
NYSE:OPTU
|
$190.79 Million |
|
Comstock Holding Companies Inc
NASDAQ:CHCI
|
$190.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rxsight Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 281,238,000 to 275,683,000, a change of -5,555,000 (-2.0%).
- Net loss of 38,943,000 reduced equity.
- New share issuances of 3,951,000 increased equity.
- Other comprehensive income decreased equity by 113,000.
- Other factors increased equity by 29,550,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.94 Million | -14.13% |
| Share Issuances | $3.95 Million | +1.43% |
| Other Comprehensive Income | $-113.00K | -0.04% |
| Other Changes | $29.55 Million | +10.72% |
| Total Change | $- | -1.98% |
Book Value vs Market Value Analysis
This analysis compares Rxsight Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-15.97 | $4.59 | x |
| 2020-12-31 | $-15.60 | $4.59 | x |
| 2021-12-31 | $5.05 | $4.59 | x |
| 2022-12-31 | $3.25 | $4.59 | x |
| 2023-12-31 | $4.65 | $4.59 | x |
| 2024-12-31 | $7.24 | $4.59 | x |
| 2025-12-31 | $6.70 | $4.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rxsight Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.96%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.13x
- Recent ROE (-14.13%) is above the historical average (-23.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 5632.31% | 0.02x | 0.00x | $156.68 Million |
| 2020 | 0.00% | 187.87% | 0.15x | 0.00x | $57.33 Million |
| 2021 | -35.22% | -215.50% | 0.12x | 1.39x | $-62.51 Million |
| 2022 | -74.25% | -136.22% | 0.33x | 1.67x | $-75.75 Million |
| 2023 | -30.31% | -54.57% | 0.49x | 1.14x | $-64.64 Million |
| 2024 | -9.76% | -19.62% | 0.44x | 1.13x | $-55.58 Million |
| 2025 | -14.13% | -28.96% | 0.43x | 1.13x | $-66.51 Million |
Industry Comparison
This section compares Rxsight Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rxsight Inc (RXST) | $263.34 Million | 0.00% | 0.34x | $190.91 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more